Humanigen Inc. (HGEN) Prices 8M Share Common Offering at $8.50/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
Humanigen Announces Pricing of Public Offering of Common Stock and Commencement of Trading on Nasdaq Under the Symbol “HGEN”
September 17, 2020 9:14 PM EDTBURLINGAME, CA / ACCESSWIRE / September 17, 2020 / Humanigen, Inc. ("Humanigen") (OTCQB: HGEND)(NASDAQ: HGEN), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm' with its lead drug candidate lenzilumab, announced today that it has priced its underwritten public offering of 8,000,000 shares of common stock at a public offering price of $8.50 per share, resulting in gross proceeds to Humanigen of approximately $68 million, before deducting underwriting discounts and commissions and offering expenses. The offering is expected to close on or about... More
